Favourable Outcome in a Patient with Central Nervous System Lupus

Journal of Association of Physicians of India

Volumn 47, Issue 12, 1999, Pages 1201-1202

  Bichile, L S ^a   Pruthi, M S ^b   Zarkar, A ^b   Sabnis, S A ^b  

^a KEM HOSPITAL   (India)

^b LOKMANYA TILAK MUNICIPAL GENERAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; FEMALE; HUMAN; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM DISEASES; CHILD; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHYLPREDNISOLONE; TREATMENT OUTCOME;

EID: 0033302572     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Fernglass EI, Arnett FC, Dorsch CA, et al. Neuropsychiatrie manifestations of systemic lupus erythemetosus : diagnosis clinical spectrum, and relationship to features of the disease. Medicine 1976; 55 : 323-9.
2. Ropes MW. Systemic lupus erythemetosus. Cambridge MA, Haward University Press. 1976.
3. Papero P, Bluestein H, Shite P, et al. Neuropsychological deficits and antineuronal antibody in paediatric systemic lupus. Clin Exp Rheumato 1990; 8 : 417-22.
4. Imbach PA. Immune thrombocytopenic purpura. From intravenous immunogloubulin therapy clinical benefits and future prospects. The Partheon Publishing Group, New York. June, 1994; 43-6.
5. Jayne D. Systemic vasculitis from intravenous immunoglobulin therapy. Clinical benefits and future prospects. The Partheon Publishing Group New York. 1994; 47-52.
6. Euler HH, Schroeder JO. Dermatomyos itis and systemic lupus erythematosus from intravenous immunoglobulin therapy clinical benefits and future prospects The Partheon Publishing Group New York. 1994; 53-7.